Programmed cell death protein 4 (pdcd4): a novel target for antineoplastic therapy?

Brigitte Lankat-Buttgereit; Rüdiger Göke

doi:10.1016/j.biolcel.2003.09.003

Programmed cell death protein 4 (pdcd4): a novel target for antineoplastic therapy?

Biol Cell. 2003 Nov;95(8):515-9. doi: 10.1016/j.biolcel.2003.09.003.

Authors

Brigitte Lankat-Buttgereit¹, Rüdiger Göke

Affiliation

¹ Clinical Research Unit for Gastrointestinal Endocrinology, University of Marburg, 35037 Marburg, Germany. [email protected]

PMID: 14630388
DOI: 10.1016/j.biolcel.2003.09.003

Abstract

Pdcd4 is a novel gene first identified as a differentially expressed protein during apoptosis. In the meantime not only the impact of Pdcd4 in programmed cell death but also an implication in transformation suppression by inhibition of protein translation is discussed. These features implicate a potential value of Pdcd4 as a molecular target in cancer therapy. This review summarizes the current knowledge about expression, structure and function of Pdcd4.

Publication types

Review

MeSH terms

Animals
Apoptosis
Apoptosis Regulatory Proteins
Eukaryotic Initiation Factor-4G / metabolism
Mice
Neoplasms / therapy
RNA-Binding Proteins / antagonists & inhibitors
RNA-Binding Proteins / chemistry
RNA-Binding Proteins / genetics*
RNA-Binding Proteins / physiology*
Tumor Suppressor Proteins / antagonists & inhibitors
Tumor Suppressor Proteins / chemistry
Tumor Suppressor Proteins / genetics*
Tumor Suppressor Proteins / physiology*
Up-Regulation

Substances

Apoptosis Regulatory Proteins
Eukaryotic Initiation Factor-4G
Pdcd4 protein, mouse
RNA-Binding Proteins
Tumor Suppressor Proteins